Effect of genetic variation in P2Y12 on TRAP-stimulated platelet response in healthy subjects

Julie H. Oestreich; Steven R. Steinhubl; Suellen P. Ferraris; Charles D. Loftin; Wendell S. Akers

doi:10.1007/s11239-014-1058-5

Effect of genetic variation in P2Y12 on TRAP-stimulated platelet response in healthy subjects

Julie H. Oestreich, Steven R. Steinhubl, Suellen P. Ferraris, Charles D. Loftin, Wendell S. Akers

Pharmaceutical Sciences

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

In platelets, thrombin receptor signaling depends upon the release of adenosine diphosphate and subsequent activation at purinergic subtype Y (P2Y) receptors. The purpose of this study is to evaluate the influence of specific P2Y₁₂ polymorphisms on platelet reactivity in healthy subjects mediated by thrombin receptor activating peptide (TRAP). We recruited a total of 29 healthy volunteers who had been previously genotyped for two polymorphisms of the P2Y₁₂ receptor: the H2 haplotype (rs2046934) and 34C>T (rs6785930). Flow cytometry and the VerifyNow assay were used to assess platelet activation and aggregation stimulated by TRAP in the presence and absence of specific receptor antagonists for the P2Y₁, P2Y₁₂, and thromboxane A2 receptors. We identified a significant recessive effect of the P2Y₁₂-receptor H2 haplotype on TRAP-induced flow cytometry. Specifically, H2/H2 carriers (n = 5) demonstrated a significant reduction in both glycoprotein IIb/IIIa receptor activation (p < 0.001) and CD62P expression (p = 0.035). While the VerifyNow assay did not reveal any effect of haplotype on TRAP-mediated platelet aggregation (p = 0.72), the H2/H2 subjects demonstrated greater platelet inhibition in the presence of cangrelor, a specific receptor antagonist for the P2Y₁₂ receptor (p = 0.023). No consistent effects of the separate 34C>T genotype (rs6785930) were demonstrated under the conditions evaluated. The findings of this study suggest a potential association between P2Y₁₂-receptor H2/H2 carriers and reduced platelet function mediated by TRAP in healthy volunteers.

Original language	English
Pages (from-to)	372-379
Number of pages	8
Journal	Journal of Thrombosis and Thrombolysis
Volume	38
Issue number	3
DOIs	https://doi.org/10.1007/s11239-014-1058-5
State	Published - Oct 2014

Bibliographical note

Funding Information:
Conflict of interest This research was supported in part by Grants from Sigma Xi National Research Society and the University of Kentucky General Clinical Research Center M01 RR02602 and awards from the American Heart Association and the Pharmaceutical Research and Manufacturers of America Foundation (J.H.O.). C.D.L. was supported by the National Institutes of Health [HL083122]. Dr. Oestreich has served as a consultant for The Medicines Company®. For the remaining authors, no potential conflicts of interest were declared.

Funding Information:
Acknowledgments The authors acknowledge the support of the Flow Cytometry and Cell Sorting Core Facility and the Center for Clinical and Translational Science at the University of Kentucky. The authors also thank Ms. Melody Montgomery for help in editing this manuscript.

Funding

Conflict of interest This research was supported in part by Grants from Sigma Xi National Research Society and the University of Kentucky General Clinical Research Center M01 RR02602 and awards from the American Heart Association and the Pharmaceutical Research and Manufacturers of America Foundation (J.H.O.). C.D.L. was supported by the National Institutes of Health [HL083122]. Dr. Oestreich has served as a consultant for The Medicines Company®. For the remaining authors, no potential conflicts of interest were declared. Acknowledgments The authors acknowledge the support of the Flow Cytometry and Cell Sorting Core Facility and the Center for Clinical and Translational Science at the University of Kentucky. The authors also thank Ms. Melody Montgomery for help in editing this manuscript.

Funders	Funder number
University of Kentucky General Clinical Research Center	M01 RR02602
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)	R01HL083122
National Heart, Lung, and Blood Institute (NHLBI)
American the American Heart Association
Pharmaceutical Research and Manufacturers of America Foundation
University of Kentucky
Sigma-Aldrich

Keywords

ADP receptors
Genetic test
P2Y12 receptor haplotype
Platelet function test
Thrombin receptor activating peptide

ASJC Scopus subject areas

Hematology
Cardiology and Cardiovascular Medicine

Access to Document

10.1007/s11239-014-1058-5

Cite this

@article{1f148b28fd974cbab5908553e2c78003,

title = "Effect of genetic variation in P2Y12 on TRAP-stimulated platelet response in healthy subjects",

abstract = "In platelets, thrombin receptor signaling depends upon the release of adenosine diphosphate and subsequent activation at purinergic subtype Y (P2Y) receptors. The purpose of this study is to evaluate the influence of specific P2Y12 polymorphisms on platelet reactivity in healthy subjects mediated by thrombin receptor activating peptide (TRAP). We recruited a total of 29 healthy volunteers who had been previously genotyped for two polymorphisms of the P2Y12 receptor: the H2 haplotype (rs2046934) and 34C>T (rs6785930). Flow cytometry and the VerifyNow assay were used to assess platelet activation and aggregation stimulated by TRAP in the presence and absence of specific receptor antagonists for the P2Y1, P2Y12, and thromboxane A2 receptors. We identified a significant recessive effect of the P2Y12-receptor H2 haplotype on TRAP-induced flow cytometry. Specifically, H2/H2 carriers (n = 5) demonstrated a significant reduction in both glycoprotein IIb/IIIa receptor activation (p < 0.001) and CD62P expression (p = 0.035). While the VerifyNow assay did not reveal any effect of haplotype on TRAP-mediated platelet aggregation (p = 0.72), the H2/H2 subjects demonstrated greater platelet inhibition in the presence of cangrelor, a specific receptor antagonist for the P2Y12 receptor (p = 0.023). No consistent effects of the separate 34C>T genotype (rs6785930) were demonstrated under the conditions evaluated. The findings of this study suggest a potential association between P2Y12-receptor H2/H2 carriers and reduced platelet function mediated by TRAP in healthy volunteers.",

keywords = "ADP receptors, Genetic test, P2Y12 receptor haplotype, Platelet function test, Thrombin receptor activating peptide",

author = "Oestreich, \{Julie H.\} and Steinhubl, \{Steven R.\} and Ferraris, \{Suellen P.\} and Loftin, \{Charles D.\} and Akers, \{Wendell S.\}",

note = "Funding Information: Conflict of interest This research was supported in part by Grants from Sigma Xi National Research Society and the University of Kentucky General Clinical Research Center M01 RR02602 and awards from the American Heart Association and the Pharmaceutical Research and Manufacturers of America Foundation (J.H.O.). C.D.L. was supported by the National Institutes of Health [HL083122]. Dr. Oestreich has served as a consultant for The Medicines Company{\textregistered}. For the remaining authors, no potential conflicts of interest were declared. Funding Information: Acknowledgments The authors acknowledge the support of the Flow Cytometry and Cell Sorting Core Facility and the Center for Clinical and Translational Science at the University of Kentucky. The authors also thank Ms. Melody Montgomery for help in editing this manuscript.",

year = "2014",

month = oct,

doi = "10.1007/s11239-014-1058-5",

language = "English",

volume = "38",

pages = "372--379",

number = "3",

}

TY - JOUR

T1 - Effect of genetic variation in P2Y12 on TRAP-stimulated platelet response in healthy subjects

AU - Oestreich, Julie H.

AU - Steinhubl, Steven R.

AU - Ferraris, Suellen P.

AU - Loftin, Charles D.

AU - Akers, Wendell S.

N1 - Funding Information: Conflict of interest This research was supported in part by Grants from Sigma Xi National Research Society and the University of Kentucky General Clinical Research Center M01 RR02602 and awards from the American Heart Association and the Pharmaceutical Research and Manufacturers of America Foundation (J.H.O.). C.D.L. was supported by the National Institutes of Health [HL083122]. Dr. Oestreich has served as a consultant for The Medicines Company®. For the remaining authors, no potential conflicts of interest were declared. Funding Information: Acknowledgments The authors acknowledge the support of the Flow Cytometry and Cell Sorting Core Facility and the Center for Clinical and Translational Science at the University of Kentucky. The authors also thank Ms. Melody Montgomery for help in editing this manuscript.

PY - 2014/10

Y1 - 2014/10

N2 - In platelets, thrombin receptor signaling depends upon the release of adenosine diphosphate and subsequent activation at purinergic subtype Y (P2Y) receptors. The purpose of this study is to evaluate the influence of specific P2Y12 polymorphisms on platelet reactivity in healthy subjects mediated by thrombin receptor activating peptide (TRAP). We recruited a total of 29 healthy volunteers who had been previously genotyped for two polymorphisms of the P2Y12 receptor: the H2 haplotype (rs2046934) and 34C>T (rs6785930). Flow cytometry and the VerifyNow assay were used to assess platelet activation and aggregation stimulated by TRAP in the presence and absence of specific receptor antagonists for the P2Y1, P2Y12, and thromboxane A2 receptors. We identified a significant recessive effect of the P2Y12-receptor H2 haplotype on TRAP-induced flow cytometry. Specifically, H2/H2 carriers (n = 5) demonstrated a significant reduction in both glycoprotein IIb/IIIa receptor activation (p < 0.001) and CD62P expression (p = 0.035). While the VerifyNow assay did not reveal any effect of haplotype on TRAP-mediated platelet aggregation (p = 0.72), the H2/H2 subjects demonstrated greater platelet inhibition in the presence of cangrelor, a specific receptor antagonist for the P2Y12 receptor (p = 0.023). No consistent effects of the separate 34C>T genotype (rs6785930) were demonstrated under the conditions evaluated. The findings of this study suggest a potential association between P2Y12-receptor H2/H2 carriers and reduced platelet function mediated by TRAP in healthy volunteers.

AB - In platelets, thrombin receptor signaling depends upon the release of adenosine diphosphate and subsequent activation at purinergic subtype Y (P2Y) receptors. The purpose of this study is to evaluate the influence of specific P2Y12 polymorphisms on platelet reactivity in healthy subjects mediated by thrombin receptor activating peptide (TRAP). We recruited a total of 29 healthy volunteers who had been previously genotyped for two polymorphisms of the P2Y12 receptor: the H2 haplotype (rs2046934) and 34C>T (rs6785930). Flow cytometry and the VerifyNow assay were used to assess platelet activation and aggregation stimulated by TRAP in the presence and absence of specific receptor antagonists for the P2Y1, P2Y12, and thromboxane A2 receptors. We identified a significant recessive effect of the P2Y12-receptor H2 haplotype on TRAP-induced flow cytometry. Specifically, H2/H2 carriers (n = 5) demonstrated a significant reduction in both glycoprotein IIb/IIIa receptor activation (p < 0.001) and CD62P expression (p = 0.035). While the VerifyNow assay did not reveal any effect of haplotype on TRAP-mediated platelet aggregation (p = 0.72), the H2/H2 subjects demonstrated greater platelet inhibition in the presence of cangrelor, a specific receptor antagonist for the P2Y12 receptor (p = 0.023). No consistent effects of the separate 34C>T genotype (rs6785930) were demonstrated under the conditions evaluated. The findings of this study suggest a potential association between P2Y12-receptor H2/H2 carriers and reduced platelet function mediated by TRAP in healthy volunteers.

KW - ADP receptors

KW - Genetic test

KW - P2Y12 receptor haplotype

KW - Platelet function test

KW - Thrombin receptor activating peptide

UR - http://www.scopus.com/inward/record.url?scp=84906940439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906940439&partnerID=8YFLogxK

U2 - 10.1007/s11239-014-1058-5

DO - 10.1007/s11239-014-1058-5

M3 - Article

C2 - 24510678

AN - SCOPUS:84906940439

SN - 0929-5305

VL - 38

SP - 372

EP - 379

JO - Journal of Thrombosis and Thrombolysis

JF - Journal of Thrombosis and Thrombolysis

IS - 3

ER -

Effect of genetic variation in P2Y12 on TRAP-stimulated platelet response in healthy subjects

Abstract

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this